EGFR Antikörper (pTyr845) (Alexa Fluor 647)

Produktnummer ABIN1177050

Produktdetails anti-EGFR Antikörper (Alexa Fluor 647)

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Bindungsspezifität: pTyr845

Reaktivität: Human, Maus, Ratte

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser EGFR Antikörper ist konjugiert mit Alexa Fluor 647

Applikation: Intracellular Staining (ICS)

Marke: BD Phosflow™

Aufreinigung: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Phosphorylated Human EGF Receptor Peptide

Klon: 12A3

Isotyp: IgG1 kappa

Anwendungsinformationen

Probenmenge: 20 μL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Aqueous buffered solution containing BSA and ≤0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The antibody was conjugated to Alexa Fluor® 647 under optimum conditions, and unreacted Alexa Fluor® 647 was removed.

Referenzen für anti-EGFR Antikörper (Alexa Fluor 647) (ABIN1177050)

Mendelsohn, Baselga: "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 21, Issue 14, pp. 2787-99, (2003) (PubMed).

Details zu EGFR

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Andere Bezeichnung: EGF Receptor (EGFR Produkte)

Synonyme: C-erb antikoerper, CG10079 antikoerper, D-EGFR antikoerper, D-Egf antikoerper, DEGFR antikoerper, DER antikoerper, DER flb antikoerper, DER/EGFR antikoerper, DER/faint little ball antikoerper, DER/top antikoerper, DER/torpedo antikoerper, DER1 antikoerper, DEgfr antikoerper, Degfr antikoerper, Der antikoerper, DmHD-33 antikoerper, Dmel\\CG10079 antikoerper, EFG-R antikoerper, EGF-R antikoerper, EGFR antikoerper, EGFr antikoerper, EGfr antikoerper, EK2-6 antikoerper, Egf antikoerper, Egf-r antikoerper, EgfR antikoerper, El antikoerper, Elp antikoerper, Elp-1 antikoerper, Elp-B1 antikoerper, Elp-B1RB1 antikoerper, HD-33 antikoerper, TOP antikoerper, Torpedo/DER antikoerper, Torpedo/Egfr antikoerper, c-erbB antikoerper, d-egf-r antikoerper, dEGFR antikoerper, dEGFR1 antikoerper, dEgfr antikoerper, der antikoerper, egfr antikoerper, flb antikoerper, l(2)05351 antikoerper, l(2)09261 antikoerper, l(2)57DEFa antikoerper, l(2)57EFa antikoerper, l(2)57Ea antikoerper, mor1 antikoerper, top antikoerper, top/DER antikoerper, top/flb antikoerper, torpedo/Egfr antikoerper, torpedo/egfr antikoerper, EGFR12 antikoerper, EGFR15 antikoerper, egfr1 antikoerper, Erbb2 antikoerper, ERBB antikoerper, ERBB1 antikoerper, HER1 antikoerper, PIG61 antikoerper, mENA antikoerper, ErbB-1 antikoerper, Errp antikoerper, 9030024J15Rik antikoerper, AI552599 antikoerper, Erbb antikoerper, Errb1 antikoerper, Wa5 antikoerper, wa-2 antikoerper, wa2 antikoerper, epidermal growth factor receptor antikoerper, Epidermal growth factor receptor antikoerper, epidermal growth factor receptor a (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) antikoerper, EGFR antikoerper, Egfr antikoerper, egfra antikoerper, egfr1 antikoerper, LOC5564544 antikoerper

Hintergrund: Epidermal Growth Factor (EGF) elicits a variety of cellular responses that are initiated by EGF Receptor (EGFR) binding and activation of intrinsic tyrosine kinase activity. EGFR, also known as ErbB1 or HER1, is a member of the ErbB class of receptor protein tyrosine kinases. It has an extracellular ligand-binding domain, a single transmembrane region, and a cytoplasmic region containing a protein tyrosine kinase domain and a c-terminal regulatory domain with many phosphorylation sites. Following ligand binding, EGFR forms homodimers and heterodimers with ErbB2. Specific C-terminal tyrosine residues are then autophosphorylated and, in turn, bind to adaptor proteins, kinases, or protein tyrosine phosphatases. In addition, c-Src-dependent phosphorylations at other sites, such as tyrosine 845 (Y845) in the kinase domain, regulate the receptor's kinase activity. Inappropriate expression or mutations of EGFR and/or deregulation of its signaling pathways are associated with many types of cancer, making EGFR a promising target for cancer therapies. The 12A3 monoclonal antibody recognizes the phosphorylated Y845 in the protein tyrosine kinase domain of human EGFR.

Pathways: NF-kappaB Signalweg, RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteine